Potential CHMP opinion moved from Q4 2018 into H1 2019Guidance for initial EU commercial launch in H2 2019 unchangedFDA meeting held under RMAT statusPhase 3 study on track with […]
Regulatory news – prior Sept 2018
To view our latest Regulatory news please click here
Amsterdam, The Netherlands, August 31, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces its unaudited interim Financial […]
31 August 2018
Amsterdam, The Netherlands, June 5, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product […]
05 June 2018
Responses submitted to EMA Day 120 list of questions Amsterdam, The Netherlands, March 28, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical […]
28 March 2018
Amsterdam-Duivendrecht, The Netherlands, September 27, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make […]
27 September 2017
Amsterdam-Duivendrecht, The Netherlands, September 20, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make […]
20 September 2017
Amsterdam-Duivendrecht, The Netherlands, August 25, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make […]
25 August 2017
Amsterdam-Duivendrecht, The Netherlands, June 9, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make […]
09 June 2017
Kiadis Pharma hosted a Key Opinion Leader meeting on the topic of ‘Addressing the Risks of Haploidentical HSCT in Blood Cancer’ on Wednesday, May 31 from 12:00pm – 1:30pm Eastern […]
22 May 2017